Clinical Research Directory
Browse clinical research sites, groups, and studies.
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
Sponsor: Vanderbilt University Medical Center
Summary
The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.
Key Details
Gender
All
Age Range
18 Years - 69 Years
Study Type
INTERVENTIONAL
Enrollment
72
Start Date
2024-02-14
Completion Date
2026-12-31
Last Updated
2026-02-04
Healthy Volunteers
No
Conditions
Interventions
2-Hydroxybenzylamine
2-Hydroxybenzylamine (2-HOBA) 250 mg three tabs TID (po) for 6 weeks.
Placebo
Placebo 250 mg three tabs TID (po) for 6 weeks.
Locations (1)
Vanderbilt University Medical Center
Nashville, Tennessee, United States